Detection and staging of recurrent or metastatic nasopharyngeal carcinoma in the era of FDG PET/MR

xlomafota13 shared this article with you from Inoreader Detection and staging of recurrent or metastatic nasopharyngeal carcinoma in the era of FDG PET/MR Via http://link.springer.com/journal/405,European archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino Eur Arch Otorhinolaryngol. 2021 Mar 29. doi: 10.1007/s00405-021-06779-5. Online ahead of print. ABSTRACT PURPOSE: The aim of this pilot study was to evaluate the accuracy of 18 fluorodeoxyglucose (FDG) PET/MR imaging in detection and staging of recurrent or metastatic NPC. PATIENTS AND METHODS: The PET/MR scans of 60 patients with clinically diagnosed recurrent or metastatic NPC between April 2017 and November 2019 were included in this study. Findings were evaluated according to the eighth edition of the American Joint Committee on Cancer staging system. Final diagnosis was confirmed at biopsy or imaging follow-up for at least 6 months. RESULTS: Of the 60 patients, 25, 26 and 42 had developed local lesions, regional nodal metastases and distant metastases, respectively. The overall accuracy of PET/MR imaging for staging of recurrent or metastatic NPC was 88.3%. CONCLUSIONS: For recurrent or metastatic NPC, 18 FDG PET /MRI might serve as a single-step staging modality. PMID:33782748 | DOI:10.1007/s00405-021-06779-5 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.